Core Insights - China Antibody-B (03681) reported a significant increase in other income and revenue, reaching 9.802 million RMB, a year-on-year increase of 126.95% [1] - The company’s flagship product, Suciraslimab (SM03), has achieved breakthrough results in preclinical studies for treating systemic lupus erythematosus (SLE), demonstrating unique advantages in regulating the autoimmune network and protecting organ damage [1][2] - The total value of license-out transactions for Chinese innovative drugs reached 66 billion USD in the first half of 2025, a 36% year-on-year increase, indicating strong international recognition of early-stage innovations from China [1] Financial Performance - Other income and revenue for the first half of 2025 amounted to 9.802 million RMB, reflecting a 126.95% increase compared to the previous year [1] - Research and development costs were reported at 32.74 million RMB [1] Product Development - Suciraslimab is the world's first monoclonal antibody targeting the CD22 site, showing significant efficacy in reducing anti-dsDNA antibody levels and improving proteinuria and renal pathology in lupus nephritis [1] - The company is optimistic about the further validation of Suciraslimab and SM17 in upcoming clinical trials, aiming to address unmet medical needs for SLE and atopic dermatitis (AD) patients [2] Regulatory Environment - The National Medical Products Administration has reduced the clinical trial approval time for innovative drugs from 14 months to 30 days, facilitating a more favorable environment for innovation [2] - The National Healthcare Security Administration's "Sixteen Policies for Innovative Drugs" is expected to expand payment support, contributing to the recovery of the Chinese innovative drug market [2]
中国抗体-B发布中期业绩 研究及开发成本3274万元 两款核心药物管线均取得突破式进展